Targeting the Cannabinoid system to produce Analgesia

Current Topics in Behavioral Neurosciences

Volumn 1, Issue , 2009, Pages 275-287

  Sagar, Devi Rani ^a   Jhaveri, Maulik ^a   Chapman, Victoria ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Arthritis; Endocannabinoid; Fatty acid amide hydrolase; Inflammation; Neuropathic

Indexed keywords

AMIDASE; CANNABINOID; CANNABINOID RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE;

ANALGESIA; ANIMAL; ARTICLE; DISEASE MODEL; HUMAN; METABOLISM; PAIN; PHYSIOLOGY;

AMIDOHYDROLASES; ANALGESIA; ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HUMANS; PAIN; RECEPTORS, CANNABINOID;

EID: 79952118399     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/978-3-540-88955-7_11     Document Type: Article

References (94)

1. Agarwal N, Pacher P, Tegeder I et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870-879
2. Bab I, Ofek O, Tam J et al. (2008) Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 20(Suppl 1):69-74
3. Beaulieu P, Bisogno T, Punwar S et al. (2000) Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396:85-92
4. Beltramo M, Bernardini N, Bertorelli R et al. (2006) CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23:1530-1538
5. Blake DR, Robson P, Ho M et al. (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45:50-52
6. Brown AJ (2007) Novel cannabinoid receptors. Br J Pharmacol 152:567-575
7. Chang L, Luo L, Palmer JA et al. (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148:102-113
8. Chapman V (1999) The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 127:1765-1767
9. Chin CL, Tovcimak AE, Hradil VP et al. (2008) Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol 153:367-379
10. Clayton N, Marshall FH, Bountra C et al. (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253-260
11. Cox ML, Welch SP (2004) The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat. Eur J Pharmacol 493:65-74
12. Cox ML, Haller VL, Welch SP (2007a) The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Eur J Pharmacol 570:50-56
13. Cox ML, Haller VL, Welch SP (2007b) Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 567:125-130
14. Cravatt BF, Giang DK, Mayfield SP et al. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87
15. Cravatt BF, Demarest K, Patricelli MP et al. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376
16. Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796
17. Devane WA, Hanus L, Breuer A et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
18. Dinh TP, Carpenter D, Leslie FM et al. (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824
19. Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422:159-171
20. Elmes SJ, JhaveriMD, Smart D et al. (2004) Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20:2311-2320
21. Elmes SJ, Winyard LA, Medhurst SJ et al. (2005) Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118:327-335
22. Fegley D, Gaetani S, Duranti A et al. (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 30-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352-358
23. Finn DP, Jhaveri MD, Beckett SR et al. (2003) Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45:594-604
24. Fowler CJ (2007) The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 152:594-601
25. Galiegue S, Mary S, Marchand J et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61
26. Gauldie SD, McQueen DS, Pertwee R et al. (2001) Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br J Pharmacol 132:617-621
27. Gong JP, Onaivi ES, Ishiguro H et al. (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10-23
28. Guindon J, Hohmann AG (2008) Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319-334
29. Guindon J, Desroches J, Beaulieu P (2007) The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150:693-701
30. Hanus L, Abu-Lafi S, Fride E et al. (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665
31. Harris J, Drew LJ, Chapman V (2000) Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. NeuroReport 11:2817-2819
32. Herkenham M, Groen BG, Lynn AB et al. (1991) Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res 552:301-310
33. Hohmann AG (2002) Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121:173-190
34. Hohmann AG, Tsou K, Walker JM (1998) Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55, 212-2. Neurosci Lett 257:119-122
35. Holt S, Comelli F, Costa B et al. (2005) Inhibitors of fatty acid amide hydrolase reduce carrageenaninduced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146:467-476
36. Huang SM, Bisogno T, Trevisani M et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99:8400-8405
37. Ibrahim MM, Porreca F, Lai J et al. (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102:3093-3098
38. Ibrahim MM, Rude ML, Stagg NJ et al. (2006) CB2 cannabinoid receptor mediation of antinociception. Pain 122:36-42
39. Iversen L, Chapman V (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2:50-55
40. Jayamanne A, Greenwood R, Mitchell VA et al. (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-288
41. Jhaveri MD, Richardson D, Kendall DA et al. (2006) Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26:13318-13327
42. Jhaveri MD, Richardson D, Chapman V (2007a) Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 152:624-632
43. Jhaveri MD, Sagar DR, Elmes SJ et al. (2007b) Cannabinoid CB(2) receptor-mediated antinociception in models of acute and chronic pain. Mol Neurobiol 36:26-35
44. Jhaveri MD, Elmes SJ, Richardson D et al. (2008a) Evidence for a novel functional role of cannabinoid CB receptors in the thalamus of neuropathic rats. Eur J Neurosci 27:1722-1730
45. Jhaveri MD, Richardson D, Robinson I et al. (2008b) Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55:85-93
46. Johns DG, Behm DJ, Walker DJ et al. (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152:825-831
47. Karsak M, Cohen-Solal M, Freudenberg J et al. (2005) Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14:3389-3396
48. Kathuria S, Gaetani S, Fegley D et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81
49. Kelly S, Chapman V (2001) Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 86:3061-3064
50. Kelly S, Chapman V (2002) Spinal administration of capsazepine inhibits noxious evoked responses of dorsal horn neurons in non-inflamed and carrageenan inflamed rats. Brain Res 935:103-108
51. Kelly S, Chapman V (2003) Cannabinoid CB(1) receptor inhibition of mechanically evoked responses of spinal neurones in control rats, but not in rats with hindpaw inflammation. Eur J Pharmacol 474:209-216
52. Kelly S, Jhaveri MD, Sagar DR et al. (2003) Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur J Neurosci 18:2239-2243
53. Lauckner JE, Jensen JB, Chen HY et al. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105:2699-2704
54. Leung D, Saghatelian A, Simon GMet al. (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45:4720-4726
55. Lichtman AH, Cook SA, Martin BR (1996) Investigation of brain sites mediating cannabinoidinduced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585-593
56. Lichtman AH, Leung D, Shelton CC et al. (2004a) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441-448
57. Lichtman AH, Shelton CC, Advani T et al. (2004b) Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109:319-327
58. Liu J, Wang L, Harvey-White J et al. (2006) A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 103:13345-13350
59. Liu J, Wang L, Harvey-White J et al. (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54:1-7
60. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122
61. Maione S, De Petrocellis L, de Novellis V et al. (2007) Analgesic actions of N-arachidonoylserotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150:766-781
62. Malan TP Jr, Ibrahim MM, Deng H et al. (2001) CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93:239-245
63. Malan TP Jr, Ibrahim MM, Lai J et al. (2003) CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3:62-67
64. Martin WJ, Coffin PO, Attias E et al. (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822:237-242
65. Mechoulam R, Ben-Shabat S, Hanus L et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
66. Meng ID, Manning BH, Martin WJ et al. (1998) An analgesia circuit activated by cannabinoids. Nature 395:381-383
67. Mitrirattanakul S, Ramakul N, Guerrero AV et al. (2006) Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126:102-114
68. Ofek O, Karsak M, Leclerc N et al. (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103:696-701
69. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611
70. Petrosino S, Palazzo E, de Novellis V et al. (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52:415-422
71. Porter AC, Sauer JM, Knierman MD et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at theCB1 receptor. J Pharmacol Exp Ther 301:1020-1024
72. Rice AS, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66:243-256
73. Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119
74. Richardson D, Pearson RG, Kurian N et al. (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10:R43
75. Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA (2008) Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 108:722-734
76. Russo R, Loverme J, La Rana G et al. (2007) The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 30-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322:236-242
77. Ryberg E, Larsson N, Sjogren S et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101
78. Sagar DR, Kelly S, Millns PJ et al. (2005) Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22:371-379
79. Schuelert N, McDougall JJ (2008) Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum 58:145-153
80. Scott DA, Wright CE, Angus JA (2004) Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109:124-131
81. Simon GM, Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283:9341-9349
82. Smith FL, Fujimori K, Lowe J et al. (1998) Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 60:183-191
83. Sokal DM, Elmes SJ, Kendall DA et al. (2003) Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 45:404-411
84. Tam J, Ofek O, Fride E et al. (2006) Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70:786-792
85. Tsou K, Brown S, Sanudo-Pena MC et al. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411
86. Tsuboi K, Takezaki N, Ueda N (2007) The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 4:1914-1925
87. Valenzano KJ, Tafesse L, Lee G et al. (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48:658-672
88. Van Sickle MD, Duncan M, Kingsley PJ et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329-332
89. Walker JM, Huang SM (2002) Cannabinoid analgesia. Pharmacol Ther 95:127-135
90. Walker JM, Huang SM, Strangman NMet al. (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96:12198-12203
91. Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262:10-18
92. Welch SP, Huffman JW, Lowe J (1998) Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286:1301-1308
93. Wright S, Ware M, Guy G (2006) The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45, 781; author reply 781-782
94. Yamamoto W, Mikami T, Iwamura H (2008) Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583:56-61